Creative Medical Technology Holdings (CELZ) Stock Price, Financials & Analysis

Key Stats

Market Cap1.06 Mn

P/E-0.18

P/S352.71

Div. Yield0.00

Add ratio to table…

About

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company dedicated to advancing regenerative therapies in immunotherapy endocrinology urology neurology and orthopedics. The company develops platforms that use a patient’s own stem cells or immune cells to treat conditions such as erectile dysfunction type 1 diabetes chronic lower back pain premature ovarian failure and other indications. Its lead platforms include ImmCelz™ a personalized immune cell therapy AlloStem™ an allogenic perinatal cell line StemSpine® a procedure for disc degeneration OvaStem™ for ovarian function CaverStem® for erectile dysfunction and FemCelz® for female sexual function. These technologies are supported by a portfolio of issued patents and pending applications covering various cell based treatments.

The company currently generates limited revenue from its CaverStem® procedure which treats erectile dysfunction. In recent years it has reported minimal revenue from this product and has paused marketing while it reevaluates the product strategy. Other platforms such as ImmCelz™ AlloStem™ StemSpine® and OvaStem™ remain in preclinical or clinical trial stages and have not yet contributed material sales. Revenue may also arise from licensing agreements or partnership collaborations but these have not been disclosed as significant sources of income.

Creative Medical Technologies Holdings, Inc. occupies a niche within the broader regenerative medicine sector where it competes with larger firms such as Mesoblast Longeveron BioRestorative Therapies and DiscGenics. Its competitive advantages stem from proprietary cell platforms patented procedures and regulatory milestones including FDA cleared investigational new drug applications orphan drug designation for its ImmCelz™ therapy and Fast Track designation for its lead candidate. The company also benefits from a deep intellectual property portfolio with seven issued patents and numerous pending applications that protect its innovations in cell based therapies. These factors position Creative Medical Technologies Holdings, Inc. as a specialized player focused on early stage clinical development rather than a large scale commercial manufacturer.

Creative Medical Technologies Holdings, Inc. serves patients suffering from a range of conditions including erectile dysfunction type 1 diabetes chronic lower back pain premature ovarian failure and other disorders targeted by its regenerative platforms. Therapy is delivered through licensed physicians and clinical trial sites rather than directly to consumers so the customer base comprises medical professionals and research institutions administering the treatments. While specific patient or clinic names are not disclosed the company focuses on individuals with unmet medical needs where existing therapies are limited or ineffective.

How Creative Medical Technology Holdings ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 22, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.17xMedian 16.9x 6^th
P/FCFNegative free cash flow −0.17xMedian 17.7x 5^th
P/Operating cash flowNegative operating cash flow −0.17xMedian 16.9x 5^th
P/S 328xMedian 9.35x 8^th
P/B 0.11xMedian 2.19x 96^th
P/Tangible book 0.12xMedian 2.39x 97^th
EV/EBITDA —Median 15.7x No data —
EV/EBITNet cash exceeds market value 1.24xMedian 19.9x Not meaningful —
EV/RevenueNet cash exceeds market value <−1,000xMedian 6.49x Not meaningful —
EV/FCFNet cash exceeds market value 1.31xMedian 19.5x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 1.31xMedian 16.2x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.34 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −50.0%Median 10.3% 16^th
Revenue CAGR (3Y) −65.6%Median 10.2% 4^th
Gross profit growth (1Y) −44.3%Median 10.6% 15^th
Gross profit CAGR (3Y) −66.2%Median 10.7% 2^nd
Operating income growth (1Y) −5.4%Median 0.0% 45^th
Operating income CAGR (3Y) 13.4%Median 1.6% 65^th
Net income growth (1Y) −4.8%Median −4.9% 50^th
Net income CAGR (3Y) 13.6%Median −0.5% 65^th
EPS growth (1Y) 27.0%Median 21.6% 55^th
EPS CAGR (3Y) 42.4%Median 25.3% 71^st
Operating cash flow growth (1Y) −3.8%Median 0.3% 46^th
Operating cash flow CAGR (3Y) 14.0%Median 2.4% 69^th
Free cash flow growth (1Y) −3.8%Median 0.3% 46^th
Free cash flow CAGR (3Y) 14.0%Median 3.3% 68^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 66.9%Median 74.0% 38^th
EBITDA margin —Median −216% No data —
Operating margin <−10,000%Median −230% 1^st
Pretax margin <−10,000%Median −223% 1^st
Net margin <−10,000%Median −230% 1^st
FCF margin <−10,000%Median −168% 1^st
Operating cash flow margin <−10,000%Median −157% 1^st
Return on equity −81.5%Median −53.6% 37^th
Return on assets −76.3%Median −42.0% 29^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −86.5%Median −46.0% 28^th
Asset turnover 0.00xMedian 0.18x 1^st
Cash conversion (OCF / net income)Net income is not positive 0.98xMedian 1.21x Not meaningful —
Stock comp / revenue —Median 27.5% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.26x No data —
Net debt / EBITDA —Median 1.82x No data —
Debt / FCF —Median 3.03x No data —
Liabilities / assets 7.4%Median 32.7% 89^th
Equity / assets 92.6%Median 67.3% 89^th
Interest coverage —Median −10.1x No data —
Current ratio 12.9xMedian 4.50x 83^rd
Quick ratio 12.5xMedian 3.74x 85^th
Cash ratio 12.5xMedian 3.35x 85^th
Altman Z-score −11.3Median −0.61 21^st

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.4% No dividend —
Net buyback yieldAbove 100% of market value −841%Median −3.4% Not meaningful —
Shareholder yieldAbove 100% of market value −841%Median −2.3% Not meaningful —
Payout ratio (earnings) —Median 50.9% No dividend —
Payout ratio (FCF) —Median 45.2% No dividend —
Dividend growth (1Y) —Median 3.6% No dividend —
Dividend CAGR (3Y) —Median 3.5% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,169.89 Bn	43.80	14.68	54.91 Bn
2	JNJ	Johnson & Johnson	648.35 Bn	40.28	6.53	44.65 Bn
3	ABBV	AbbVie Inc.	504.24 Bn	79.91	7.83	70.82 Bn
4	MRK	Merck & Co., Inc.	365.96 Bn	115.33	5.50	53.91 Bn
5	NVS	Novartis Ag	303.28 Bn	19.23	5.54	9.59 Bn
6	AZN	Astrazeneca Plc	268.68 Bn	25.72	4.58	32.35 Bn
7	AMGN	Amgen Inc	242.76 Bn	27.77	6.37	57.30 Bn
8	CELZ	Creative Medical Technology Holdings, Inc.	0.00 Bn	-0.18	352.71	-

Creative Medical Technology Holdings CELZ

About

How Creative Medical Technology Holdings ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Creative Medical Technology Holdings CELZ

About

How Creative Medical Technology Holdings ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password